CHRS

Coherus Oncology, Inc.

Price Chart

Latest Quote

$1.48

+0.09 (+6.47%)

Current Price

Previous Close	$1.39
Open	$1.44
Day High	$1.49
Day Low	$1.39
Volume	1,256,872

Fetched: 2026-06-19T16:42:33

Stock Information

Shares Outstanding	154.25M
Total Debt	$54.37M
Cash Equivalents	$167.05M
Revenue	$46.88M
Net Income	$-172.66M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$228.29M
EPS (TTM)	$-1.42
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$100.19M
Sales	$46.88M
Income	$-172.66M
Book/sh	$0.51
Cash/sh	$1.08
Employees	145

Financial Ratios

Quick Ratio	1.43
Current Ratio	1.56
Debt/Eq	69.16

Returns & Margins

ROA	-32.80%
Gross Margin	68.06%
Operating Margin	-293.67%
Profit Margin	397.30%

Ownership

Insider Ownership	18.66%
Institutional Ownership	38.65%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.45
P/S	4.87
P/B	2.90

Analyst Data

Recommendation	none
Target Price	$7.80

Technical Indicators

SMA20	$1.50
SMA50	$1.65
SMA200	$1.61
RSI	41.91
ATR	0.0852

Shares Float	132.53M
Short Float	18.62%
Short Ratio	20.47
Volatility	0.96
Rel Volume	1.41

Performance History

Week	+4.23%
Month	+0.00%
Quarter	-8.07%
6 Months	+6.47%
YTD	+8.03%
Year	+95.25%
3 Years	-72.79%
5 Years	-89.79%
10 Years	-90.53%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$1.48	1,288,500
2026-06-17	$1.39	646,200
2026-06-16	$1.38	1,116,600
2026-06-15	$1.36	707,900
2026-06-12	$1.40	506,300
2026-06-11	$1.42	787,100
2026-06-10	$1.36	657,500
2026-06-09	$1.42	691,500
2026-06-08	$1.42	622,300
2026-06-05	$1.45	908,700
2026-06-04	$1.58	839,700
2026-06-03	$1.47	1,036,500
2026-06-02	$1.52	894,800
2026-06-01	$1.57	817,400
2026-05-29	$1.59	1,531,400
2026-05-28	$1.65	494,900
2026-05-27	$1.66	1,191,600
2026-05-26	$1.64	1,268,800
2026-05-22	$1.61	919,200
2026-05-21	$1.57	1,393,000
2026-05-20	$1.51	702,300
2026-05-19	$1.48	1,375,900

About Coherus Oncology, Inc.

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

📰 Latest News

What You Need To Know About The Coherus Oncology, Inc. (NASDAQ:CHRS) Analyst Downgrade Today

Simply Wall St. • 2026-05-14T12:16:23Z

Coherus Oncology, Inc. Q1 2026 Earnings Call Summary

Moby • 2026-05-12T12:30:00Z

Coherus Oncology Inc (CHRS) Q1 2026 Earnings Call Highlights: Strong LOQTORZI Sales Growth Amid ...

GuruFocus.com • 2026-05-12T07:07:53Z

Coherus Oncology Q1 Earnings Call Highlights

MarketBeat • 2026-05-11T23:05:12Z

Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates

Zacks • 2026-05-11T22:05:03Z

Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More

24/7 Wall St. • 2026-05-11T11:58:15Z

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Zacks • 2026-05-05T13:40:02Z

Is Brookdale Senior Living (BKD) Outperforming Other Medical Stocks This Year?

Zacks • 2026-04-16T13:40:03Z

Coherus Oncology (CHRS) Is One of the Best Penny Stocks, Here is Why – Corrected

Insider Monkey • 2026-04-10T05:14:09Z

Why The Coherus Oncology (CHRS) Story Is Shifting Around Growth Assumptions And Execution Risk

Simply Wall St. • 2026-04-01T23:12:11Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$13,814,000	$8,727,000	$158,992,000	$70,083,000
Cost Of Revenue	$13,814,000	$8,727,000	$158,992,000	$70,083,000
Total Revenue	$42,172,000	$26,389,000	$257,244,000	$211,042,000
Operating Revenue	$42,172,000	$26,389,000	$257,244,000	$211,042,000
Expenses
Interest Expense	$9,001,000	$10,734,000	$40,542,000	$32,474,000
Total Expenses	$223,306,000	$226,042,000	$460,443,000	$467,922,000
Other Income Expense	$7,011,000	$-5,007,000	$5,469,000	$-2,400,000
Other Non Operating Income Expenses	$7,011,000	$7,623,000	$5,469,000	$3,822,000
Net Non Operating Interest Income Expense	$-9,001,000	$-10,734,000	$-40,542,000	$-32,474,000
Interest Expense Non Operating	$9,001,000	$10,734,000	$40,542,000	$32,474,000
Operating Expense	$209,492,000	$217,315,000	$301,451,000	$397,839,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-183,124,000	$-215,394,000	$-237,892,000	$-291,754,000
Net Interest Income	$-9,001,000	$-10,734,000	$-40,542,000	$-32,474,000
Normalized Income	$-183,124,000	$-202,764,000	$-237,892,000	$-285,532,000
Net Income From Continuing And Discontinued Operation	$168,024,000	$28,507,000	$-237,892,000	$-291,754,000
Total Operating Income As Reported	$-181,134,000	$-199,653,000	$-203,199,000	$-256,880,000
Net Income Common Stockholders	$168,024,000	$28,507,000	$-237,892,000	$-291,754,000
Net Income	$168,024,000	$28,507,000	$-237,892,000	$-291,754,000
Net Income Including Noncontrolling Interests	$168,024,000	$28,507,000	$-237,892,000	$-291,754,000
Net Income Discontinuous Operations	$351,148,000	$243,901,000	-	-
Net Income Continuous Operations	$-183,124,000	$-215,394,000	$-237,892,000	$-291,754,000
Pretax Income	$-183,124,000	$-215,394,000	$-238,272,000	$-291,754,000
Special Income Charges	$0	$-12,630,000	$0	$-6,222,000
Operating Income	$-181,134,000	$-199,653,000	$-203,199,000	$-256,880,000
Gross Profit	$28,358,000	$17,662,000	$98,252,000	$140,959,000
Average Dilution Earnings	-	-	-	$0
Per Share
Diluted EPS	$1.43	$0.25	$-2.53	$-3.76
Basic EPS	$1.43	$0.25	$-2.53	$-3.76
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-170,199,000	$-186,754,000	$-193,939,000	$-249,359,000
Total Unusual Items	$0	$-12,630,000	$0	$-6,222,000
Total Unusual Items Excluding Goodwill	$0	$-12,630,000	$0	$-6,222,000
Reconciled Depreciation	$3,924,000	$5,276,000	$3,791,000	$3,699,000
EBITDA (Bullshit earnings)	$-170,199,000	$-199,384,000	$-193,939,000	$-255,581,000
EBIT	$-174,123,000	$-204,660,000	$-197,730,000	$-259,280,000
Diluted Average Shares	$117,143,457	$114,830,462	$94,162,637	$77,630,020
Basic Average Shares	$117,143,457	$114,553,537	$94,162,637	$77,630,020
Diluted NI Availto Com Stockholders	$168,024,000	$28,507,000	$-237,892,000	$-291,754,000
Tax Provision	$0	$0	$-380,000	$0
Research And Development	$108,888,000	$91,833,000	$109,436,000	$199,358,000
Selling General And Administration	$100,604,000	$125,482,000	$192,015,000	$198,481,000
Gain On Sale Of Business	-	$176,589,000	$0	$0
Other Special Charges	-	$12,630,000	-	$6,222,000

Fetched: 2026-06-16

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$14,775,000	$-185,636,000	$-265,098,000	$-143,349,000
Total Assets	$258,343,000	$448,533,000	$629,604,000	$480,847,000
Total Non Current Assets	$51,637,000	$106,950,000	$153,973,000	$99,613,000
Other Non Current Assets	$4,053,000	$50,728,000	$77,181,000	$84,928,000
Goodwill And Other Intangible Assets	$46,239,000	$53,646,000	$71,673,000	$5,931,000
Other Intangible Assets	$46,239,000	$53,646,000	$70,730,000	$4,988,000
Current Assets	$206,706,000	$341,583,000	$475,631,000	$381,234,000
Other Current Assets	$6,233,000	$10,222,000	$11,099,000	$22,918,000
Assets Held For Sale Current	$0	$72,180,000	-	-
Prepaid Assets	$6,758,000	$6,653,000	$23,657,000	$17,880,000
Inventory	$3,172,000	$4,207,000	$62,605,000	$38,791,000
Receivables	$18,418,000	$122,334,000	$260,522,000	$109,964,000
Other Receivables	$603,000	$11,010,000	-	-
Accounts Receivable	$17,815,000	$111,324,000	$260,522,000	$109,964,000
Cash Cash Equivalents And Short Term Investments	$172,125,000	$125,987,000	$117,748,000	$191,681,000
Cash And Cash Equivalents	$88,879,000	$125,987,000	$102,891,000	$63,547,000
Debt
Total Debt	$40,336,000	$269,904,000	$480,842,000	$480,422,000
Long Term Debt And Capital Lease Obligation	$38,508,000	$268,213,000	$478,697,000	$476,104,000
Long Term Debt	$37,051,000	$264,927,000	$473,369,000	$471,058,000
Current Debt And Capital Lease Obligation	$1,828,000	$1,691,000	$2,145,000	$4,318,000
Net Debt	-	$138,940,000	$370,478,000	$407,511,000
Liabilities
Total Liabilities Net Minority Interest	$197,329,000	$580,523,000	$823,029,000	$618,265,000
Total Non Current Liabilities Net Minority Interest	$55,453,000	$297,542,000	$491,258,000	$479,571,000
Other Non Current Liabilities	$15,843,000	$28,227,000	$11,459,000	$3,467,000
Non Current Deferred Liabilities	$1,102,000	$1,102,000	$1,102,000	$0
Non Current Deferred Taxes Liabilities	$1,102,000	$1,102,000	$1,102,000	$0
Current Liabilities	$141,876,000	$282,981,000	$331,771,000	$138,694,000
Other Current Liabilities	$1,490,000	$13,620,000	-	-
Payables And Accrued Expenses	$123,979,000	$249,326,000	$308,105,000	$111,766,000
Payables	$9,915,000	$28,456,000	$35,219,000	$11,526,000
Accounts Payable	$9,915,000	$28,456,000	$35,219,000	$11,526,000
Equity
Common Stock Equity	$61,014,000	$-131,990,000	$-193,425,000	$-137,418,000
Total Equity Gross Minority Interest	$61,014,000	$-131,990,000	$-193,425,000	$-137,418,000
Stockholders Equity	$61,014,000	$-131,990,000	$-193,425,000	$-137,418,000
Gains Losses Not Affecting Retained Earnings	$-195,000	$-275,000	$-248,000	$-249,000
Other Equity Adjustments	$-195,000	$-275,000	$-248,000	$-249,000
Retained Earnings	$-1,382,969,000	$-1,550,993,000	$-1,579,500,000	$-1,341,608,000
Other
Ordinary Shares Number	$121,154,925	$115,614,548	$112,215,260	$78,851,516
Share Issued	$121,154,925	$115,614,548	$112,215,260	$78,851,516
Tangible Book Value	$14,775,000	$-185,636,000	$-265,098,000	$-143,349,000
Invested Capital	$98,065,000	$132,937,000	$279,944,000	$333,640,000
Working Capital	$64,830,000	$58,602,000	$143,860,000	$242,540,000
Capital Lease Obligations	$3,285,000	$4,977,000	$7,473,000	$9,364,000
Total Capitalization	$98,065,000	$132,937,000	$279,944,000	$333,640,000
Additional Paid In Capital	$1,444,166,000	$1,419,266,000	$1,386,312,000	$1,204,431,000
Capital Stock	$12,000	$12,000	$11,000	$8,000
Common Stock	$12,000	$12,000	$11,000	$8,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$1,457,000	$3,286,000	$5,328,000	$5,046,000
Current Capital Lease Obligation	$1,828,000	$1,691,000	$2,145,000	$4,318,000
Pensionand Other Post Retirement Benefit Plans Current	$14,579,000	$18,344,000	$21,521,000	$22,610,000
Current Accrued Expenses	$114,064,000	$220,870,000	$272,886,000	$100,240,000
Net PPE	$1,345,000	$2,576,000	$5,119,000	$8,754,000
Accumulated Depreciation	$-15,233,000	$-20,988,000	$-20,651,000	$-20,157,000
Gross PPE	$16,578,000	$23,564,000	$25,770,000	$28,911,000
Leases	$5,763,000	$5,751,000	$5,751,000	$6,198,000
Machinery Furniture Equipment	$10,815,000	$18,074,000	$17,725,000	$17,385,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$83,246,000	$0	$14,857,000	$128,134,000
Goodwill	-	$0	$943,000	$943,000
Other Properties	-	$-261,000	$2,294,000	$4,632,000
Construction In Progress	-	-	$0	$696,000

Fetched: 2026-06-16

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-138,513,000	$-20,440,000	$-174,884,000	$-241,124,000
Operating Activities
Operating Cash Flow	$-138,513,000	$-20,440,000	$-174,884,000	$-241,124,000
Cash Flow From Continuing Operating Activities	$-138,513,000	$-20,440,000	$-174,884,000	$-241,124,000
Operating Gains Losses	$-315,421,000	$-158,916,000	$375,000	$41,222,000
Investing Activities
Investing Cash Flow	$375,087,000	$230,321,000	$144,640,000	$-166,850,000
Cash Flow From Continuing Investing Activities	$375,087,000	$230,321,000	$144,640,000	$-166,850,000
Net Other Investing Changes	$-342,000	$110,000	$-492,000	$-4,468,000
Capital Expenditure	-	-	$-286,000	$-2,039,000
Financing Activities
Issuance Of Capital Stock	$7,894,000	$1,455,000	$71,718,000	$6,358,000
Financing Cash Flow	$-273,705,000	$-186,974,000	$69,600,000	$54,326,000
Cash Flow From Continuing Financing Activities	$-273,705,000	$-186,974,000	$69,600,000	$54,326,000
Net Other Financing Charges	$-1,115,000	$34,053,000	$-4,621,000	$-4,972,000
Net Common Stock Issuance	$7,894,000	$1,455,000	$71,718,000	$6,358,000
Common Stock Issuance	$7,894,000	$1,455,000	$71,718,000	$6,358,000
Other
Repayment Of Debt	$-280,837,000	$-260,387,000	$0	$-190,750,000
Interest Paid Supplemental Data	$9,916,000	$25,376,000	$37,857,000	$34,878,000
Income Tax Paid Supplemental Data	$36,000	-	-	$40,000
End Cash Position	$89,119,000	$126,250,000	$103,343,000	$63,987,000
Beginning Cash Position	$126,250,000	$103,343,000	$63,987,000	$417,635,000
Changes In Cash	$-37,131,000	$22,907,000	$39,356,000	$-353,648,000
Proceeds From Stock Option Exercised	$353,000	$926,000	$2,503,000	$3,011,000
Net Issuance Payments Of Debt	$-280,837,000	$-223,408,000	$0	$49,929,000
Net Long Term Debt Issuance	$-280,837,000	$-223,408,000	$0	$49,929,000
Long Term Debt Payments	$-280,837,000	$-260,387,000	$0	$-190,750,000
Net Investment Purchase And Sale	$-82,376,000	$14,888,000	$138,135,000	$-127,382,000
Sale Of Investment	$21,462,000	$14,888,000	$157,642,000	$0
Purchase Of Investment	$-103,838,000	$0	$-19,507,000	$-127,382,000
Net Business Purchase And Sale	$457,805,000	$215,323,000	$6,997,000	$-35,000,000
Sale Of Business	$470,305,000	$227,823,000	$6,997,000	$0
Purchase Of Business	$-12,500,000	$-12,500,000	$0	$-35,000,000
Change In Working Capital	$-5,842,000	$55,894,000	$-36,826,000	$-79,257,000
Change In Other Working Capital	$64,446,000	-	-	$596,000
Change In Payables And Accrued Expense	$-151,847,000	$-65,330,000	$142,409,000	$-27,323,000
Change In Accrued Expense	$-132,291,000	$-61,392,000	$118,649,000	$-22,775,000
Change In Payable	$-19,556,000	$-3,938,000	$23,760,000	$-4,548,000
Change In Account Payable	$-19,556,000	$-3,938,000	$23,760,000	$-4,548,000
Change In Prepaid Assets	$5,110,000	$3,826,000	$18,182,000	$-17,638,000
Change In Inventory	$-17,108,000	$-31,952,000	$-46,734,000	$-47,348,000
Change In Receivables	$93,557,000	$149,350,000	$-150,683,000	$13,052,000
Changes In Account Receivables	$93,557,000	$149,350,000	$-150,683,000	$13,052,000
Other Non Cash Items	$-10,328,000	$82,000	$-37,000	$8,229,000
Stock Based Compensation	$16,966,000	$27,802,000	$43,110,000	$50,737,000
Asset Impairment Charge	$4,164,000	$20,915,000	$52,595,000	$26,000,000
Depreciation Amortization Depletion	$3,924,000	$5,276,000	$3,791,000	$3,699,000
Depreciation And Amortization	$3,924,000	$5,276,000	$3,791,000	$3,699,000
Gain Loss On Investment Securities	$12,608,000	$5,043,000	$375,000	$35,000,000
Gain Loss On Sale Of Business	$-338,315,000	$-176,589,000	$0	$0
Net Income From Continuing Operations	$168,024,000	$28,507,000	$-237,892,000	$-291,754,000
Issuance Of Debt	-	$36,979,000	$0	$240,679,000
Long Term Debt Issuance	-	$36,979,000	$0	$240,679,000
Net PPE Purchase And Sale	-	-	$559,000	$-2,039,000
Sale Of PPE	-	-	$845,000	$0
Purchase Of PPE	-	-	$-286,000	$-2,039,000
Amortization Of Securities	-	-	$-3,052,000	$-730,000
Effect Of Exchange Rate Changes	-	-	-	-

Fetched: 2026-06-16